Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-23T11:33:21.821Z Has data issue: false hasContentIssue false
  • English
  • Français

Preliminary absorbed dose evaluation of two novel 153Sm bone-seeking agents for radiotherapy of bone metastases: comparison with 153Sm-EDTMP

Published online by Cambridge University Press:  08 May 2015

Hassan Yousefnia ,
Samaneh Zolghadri ,
A. Reza Jalilian  and
Zohreh Naseri
Hassan Yousefnia
Affiliation:
Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
Samaneh Zolghadri*
Affiliation:
Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
A. Reza Jalilian
Affiliation:
Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
Zohreh Naseri
Affiliation:
School of Chemistry, University College of Science, University of Tehran, Tehran, Iran
*
Correspondence to: Samaneh Zolghadri, Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran. Tel: +982188221103. Fax: +982188221105. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Aim

The amount of energy deposited on any organ by ionising radiation termed absorbed dose, plays an important role in evaluating the risks associated with the administration of radiopharmaceuticals. In this research work, the absorbed dose received by human organs for 153Sm-TTHMP and 153Sm-PDTMP was evaluated based on biodistribution studies on the Syrian rats.

Materials and methods

153Sm-TTHMP and 153Sm-PDTMP were successfully prepared with radiochemical purity of higher than 99%. The biodistribution of the complexes was investigated within the Syrian rats up to 48 hours post injection. The human absorbed dose of the complexes was estimated by the radiation dose assessment resource method.

Results

The highest absorbed dose for 153Sm-TTHMP and 153Sm-PDTMP was observed in the trabecular bone with 1·085 and 1·826 mGy/MBq, respectively. The bone to other critical organ dose ratio for 153Sm-PDTMP is significantly greater than 153Sm-TTHMP. Also, the bone/red marrow dose ratio for these complexes is comparable with this ratio for 153Sm-EDTMP, as the most clinically used Sm-153 bone pain palliative radiopharmaceutical.

Findings

According to the considerable bone absorbed dose against the insignificant absorbed dose of non-target organs, these complexes can be used as potential bone pain palliative agents in clinical applications.

Keywords

internal dosimetryPDTMPRADAR methodSm-153TTHMP
Type
Original Articles
Information
Journal of Radiotherapy in Practice , Volume 14 , Issue 3 , September 2015 , pp. 252 - 259
Check for updates
Copyright
© Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Serafini, A N. Therapy of metastatic bone pain. J Nucl Med 2001; 42: 895–906.Google ScholarPubMed
2.Pandit-Taskar, N, Batraki, M, Divgi, C R. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004; 45: 1358–1365.Google ScholarPubMed
3.IAEA-TECDOC-1549. Criteria for Palliation of Bone Metastases – Clinical Applications. Vienna: IAEA, 2007.Google Scholar
4.Lipton, A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol 2004; 2: 205–220.Google ScholarPubMed
5.Eary, J F, Collins, C, Stabin, Met al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993; 34: 1031–1036.Google ScholarPubMed
6.Bouchet, L G, Bolch, W E, Goddu, S Met al. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med 2000; 41: 682–687.Google ScholarPubMed
7.Ouadi, A, Loussouarn, A, Morandeau, Let al. Influence of trans-l,2-diaminocyclohexane structure and mixed carboxylic/phosphonic group combinationson samarium-153 chelation capacity and stability. Eur J Med Chem 2004; 39: 467–472.CrossRefGoogle Scholar
8.Pandit-Taskar, N, Batraki, M, Divgi, C R. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004; 45: 1358–1365.Google ScholarPubMed
9.Majali, M A, Mathakar, A R, Shimpi, H Het al. Studies on the preparation and stability of samarium-153 propylene diamine tetramethylene phosphonate (PDTMP) complex as a bone seeker. Appl Radiat Isotopes 2000; 53: 987–991.CrossRefGoogle ScholarPubMed
10.Naseri, Z, Jalilian, A R, Nemati Kharat, Aet al. Production, quality control and biological evaluation of 153Sm-TTHMP as a possible bone palliation agent. Iran J Nucl Med 2011; 19: 60–68.Google Scholar
11.Stabin, M G, Tagesson, M, Thomas, S Ret al. Radiation dosimetry in nuclear medicine. Appl Radiat Isot 1996; 50: 73–87.CrossRefGoogle Scholar
12.Stabin, M G, Siegel, J A. Physical models and dose factors for use in internal dose assessment. Health Phys 2003; 85: 294–310.CrossRefGoogle ScholarPubMed
13.IAEA-TECDOC-1401. Quantifying Uncertainty in Nuclear Analytical Measurements. Vienna: IAEA, 2004.Google Scholar
14.Sparks, R B, Aydogan, B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. Sixth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN: Oak Ridge Associated Universities. 1996: 705–716.Google Scholar
15.Yousefnia, H, Zolghadri, S, Jalilian, A Ret al. Preliminary dosimetric evaluation of (166)Ho-TTHMP for human based on biodistribution data in rats. Appl Radiat Isot 2014; 94: 260–265.CrossRefGoogle ScholarPubMed
16.Bevelacqua, J J. Internal dosimetry primer. Radiat Prot Manage 2005; 22: 7–17.Google Scholar
17.Turner, J H, Martindale, A A, Sorby, Pet al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 1989; 15: 784–795.CrossRefGoogle ScholarPubMed